Leyden Labs is developing antibody-based nasal sprays that aim to stop viruses like flu and covid at the mucosa and with broad protection

Oct 9, 2024
1 min read

Co-founder and CEO Koenraad Wiedhaup describes the shortcomings of today’s vaccines and why the company has chosen this unique approach. Plus, the history of virology expertise in Leiden and how Leyden Labs has attracted a slate of A-list life sciences investors.

https://vimeo.com/1017744016

Recent Posts

See All

Quell Tx believes that restoring immune balance rather than entirely depleting cells is key for many autoimmune conditions - a phase 1/2 for its CAR-Treg initiated today in RA & Systemic Sclerosis

Protagonist Therapeutics has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point

Cambridge, UK based Arecor uses formulation and development expertise to improve the profile of medicines - the company believes it has its own best in class insulin leveraging this

Leyden Labs is developing antibody-based nasal sprays that aim to stop viruses like flu and covid at the mucosa and with broad protection

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight